Computerized tests of cognitive decline in presymptomatic Alzheimer’s disease

阿尔茨海默病症状前认知能力下降的计算机化测试

基本信息

批准号：
10039211
负责人：
Peter Pebler
金额：
$ 20.23万
依托单位：
NEUROBEHAVIORAL SYSTEMS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-12-01 至 2022-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10039211
关键词：
Administrative Supplement Affect Age Alzheimer&apos s Disease Alzheimer&apos s disease pathology Alzheimer&apos s disease risk American Benchmarking California Clinic Clinical Trials Cognitive Computer Security Cooperative Research and Development Agreement Data Data Analyses Data Protection Data Security Databases Dementia Deterioration Enrollment Ensure Funding Generations Genetic Risk Goals Gold Health Insurance Portability and Accountability Act Healthcare Healthcare Systems Hospitals Hour Human Resources Impaired cognition Individual Infrastructure Institutional Review Boards Licensing Literature Longitudinal Studies Manuals Manuscripts Medical Medical center Memory Paper Participant Patient Recruitments Patients Peer Review Phase Play Population Procedures Property Protocols documentation Psychometrics Publications Research Research Design Research Personnel Resources Risk Role Scientist Secure Site Software Engineering Systems Integration Test Result Testing Training care burden cloud based cognitive testing computerized cost data hosting data management design field study inclusion criteria innovation interest meetings mental function novel therapeutics outreach recruit software development success symposium therapy design usability volunteer web site

项目摘要

Abstract. We are requesting an administrative supplement to expand participant recruitment and testing to the VA Northern California Healthcare System (VANCHCS) in Martinez. The supplement would reduce five potential risks to the long-term scientific impact of second generation California Cognitive Assessment Battery (CCAB-2) tests: • Recruitment. Participant recruitment has been compromised by the establishment of a California-funded Alzheimer’s Disease Research Center at our original recruitment site. Expanding recruitment and testing to the VANCHCS will resolve this problem and increase participant diversity: there are more than 32,000 eligible older participants within the VANCHCS catchment who meet study inclusion criteria. • Milestone completion. Our research plan calls for nearly 5,000 assessments over three years, with nearly 2,300 assessments planned in Phase II, year 1. This would require 9.1 assessments per day during year 1, i.e. approximately 20 hours of testing. The assistance of trained VA staff and the established VANCHCS’ infrastructure will assist us in meeting these testing challenges. • CCAB-2 compatibility with hospital data security protocols. In the original application, CCAB-2 testing was limited to NBS offices. The supplement will support the software development and testing needed to ensure that CCAB-2 tests function within secure healthcare IT networks with extensive data protection safeguards and HIPAA-compliant protocols. • CCAB-2 usability and robustness. In the original application, CCAB-2 test administration was limited to NBS personnel. This administrative supplement will enable extensive field testing by VA scientists and clinicians to ensure CCAB-2 robustness and usability prior to commercial launch. • Disseminating results. The extensive testing demands in the original application would limit NBS scientific outreach. The supplement will support VA scientists in publicizing CCAB-2 capabilities at conferences, Alzheimer’s Disease Centers, grand rounds, research labs, department colloquia, and in peer-reviewed publications.

抽象的。我们要求进行行政补充，以扩大参与者招聘并测试马丁内斯的VA北加州医疗保健系统（VANCHCS）。这补充将使五个潜在风险降低到第二个的长期科学影响加州一代认知评估电池（CCAB-2）测试： • 招聘。通过建立A 加利福尼亚州资助的阿尔茨海默氏病研究中心在我们的原始招聘现场。将招聘和测试扩大到VANCHC将解决此问题并增加参与者的多样性：内部有32,000多名合格的年长参与者符合学习纳入标准的Vanchcs集水区。 •里程碑完成。我们的研究计划要求三个超过三个评估年份，在第一阶段（第1年）计划了近2300次评估。这将需要9.1 在第1年的每天评估，即大约20个小时的测试。协助经过培训的VA工作人员和已建立的VANCHCS的基础设施将帮助我们见面测试挑战。 •CCAB-2与医院数据安全协议的兼容性。在原始应用中， CCAB-2测试仅限于NBS办事处。补充剂将支持软件开发和测试需要确保CCAB-2测试在安全中起作用具有广泛数据保护保障措施和符合HIPAA的医疗保健IT网络协议。 •CCAB-2可用性和鲁棒性。在原始应用中，CCAB-2测试管理仅限于NBS人员。这种行政补充剂将实现广泛的领域 VA科学家和临床医生的测试以确保CCAB-2的鲁棒性和可用性商业发布。 •传播结果。原始申请中的广泛测试要求将限制 NBS科学外展。该补充剂将支持VA科学家发布CCAB-2 会议的能力，阿尔茨海默氏病中心，大回合，研究实验室，部门校长，并在同行评审的出版物中。